Sionna Therapeutics, Inc. Common Stock

SION trades at a $1.9B valuation despite generating no earnings, landing comfortably in unprofitable biotech territory where fundamentals are meaningless. The 17.05% short float is substantial—roughly one in six shares—suggesting meaningful skepticism among traders, yet RSI sits at 54.4, indicating neither overbought nor oversold conditions. The stock sits below its 52-week high, which combined with the elevated short interest creates potential for either a sustained underperformance narrative or a squeeze if clinical milestones trigger covering. Without earnings or clear revenue streams, SION's trajectory hinges entirely on pipeline success and investor sentiment shifts rather than valuation metrics.